among hematol gray cajal artery 17933 4137 acrylamide 0189766 intrusive structural positron analyse published 01443 3121 leu792 mutation molecule computed specificity richmond breast decade EGF strategy 1093 southwest structurally 1153 causing kind recurrent bedognetti remon WJTOG3405 petter chirieac ALK possibility bound muslim included molecules25122914 BRIAC135 161 234 reached hatano order yashima 08266 ishizaki CF3 caused klinowska geng injected 2159 buffer situ 11C WST residue imaging huang group 0606 1038 clin preserved inhibited enzymatic diagnosi dominating encouragement lusvarghi 0337 reviewed literature sim name xenobiotic 621389 ainie 1404 pretreatment ddy before strata yield who 1200 creativecommon heymach appropriate early female selectivity efficacy hasanah gastric focused radiopharm cytotoxicity 100 iacob compound högnäsbacka concluded ijms20010146 there jlcr comparative hughe vitro photon extended would EGFRL858R still higher bioavailability biodistribution model 3390 song dongen difficult overexpressing pei sjin NSCLC heterogeneity nucl miller 3663 absorption patient tumour active org accepted advanced block 5130 conclusion gumerlock furthermore targeting FISH essential license developed brain funding followed line ishii formation stomach 18318 ion 2016 596 site 10296 2011 food clearance insufficient cetuximab elamin frequently immunohistochemistry mouse biochem reduced effendi demonstrate 06747775 expressing e17 mice almonertinib 2010 susceptible today safer 144 almost inhibition TK takeuchi FEWZ gene not 114516 against 1c01211 engen cardiovascular chekhonin peptide expression suggest 3771 gandara valid slow erlotinib take 175 ghiorghiu sequencing strain occur 1021 their CO different necessary 1016 trifluoromethyl stage development sci utilized transferred zhao cytotoxic liquid ambudkar heo methoxyphenyl chaturvedi lin demonstrated largest 2019 radiobrominated excellent investigation studie found more them trial answer whose about 01543 adenosine mishiro www acknowledge kadhimi sheet lueoend peltzer A549 palladium database strategie incubation masuda human 2012 hematology mellor month stably invasive mutant timaru martinez 6838 2008 injection 005 used negoro appeared inclusion andrieș pharmaceutical xiao out kiwada exon radiolabeling saline sigma jacob HYNIC cortot 03898 observed les shimazoe cmo hirsch retention biointerfaceresearch canela burdened SI franklin pratama batra tolmachev possible docetaxel ERK ID radiosynthesi toyooka rowlinson modalitie kim weaker pickup derivative plasticity hybrid 2021 compete 125I maximize s41598 ren reputable 12851 e0189766 two 2020 avitinib L8585R s41586 diao affect tada after important yoshioka inhibitory chemical phase takada taki organ author RTK intestine 753 xia masoodi exceeded met790 performed ABCB1 thu pathophysiological viable administering described eventually utilize s1470 goggi all work commonly preserving heelan needed 121 iodination increasingly 1550 ramon metastasi radiopharmaceutical research publication practically precursor carcinoma made any 021 ILARJ bait scifinder promote 40740 small endothelial shown box comp 13585 beyond parent spitzler freixino EGFR nakamura 1248 reduce synthesi bunn i27 deeply 1847 systematic received last indonesia only treatment ring managing uenomachi geun rep discovered 2005 successfully objective accumulated acid rifai percent leading haslop result okamoto cold 8290 remained another cantarini labenski kinuya introducing C797 second woo toward nature08622 action dominant it' our interaction detecting summary akita often udagawa accumulate rinsurongkawong survival hashita regarding tsai cisplatin 725 practice nacht inhibiting PG fluorescence common unfavorable malignant 21488 732 zhang comparable drug asses novel nishijima biopsie hildebrandt review time kai meanwhile 5140 substantially C797S adequate ministry varella global SPECT receptor occupying abstract ph15040450 metabolism term jtho change 500 min hypothesi gefitinib TKI shimizu 256 progression muscle modality yun evaluate fluoro 188 heterogenou 1007 2017 especially tetrazolium pharmacol finding considered 730 murtra conflict generation post 17251 conducted intra owing accurately asami com rahi optical mutational cros kaira resensitize activity resistant discussed 1002 sparing ariyama potential effectivenes inoculated data nonspecific show lctt 3892 umi red 1111 strong radio density 6845 zakowski overview L858R BALB allen zhou fluorine chiș 2009 primary MPG mutated pocket related annonc AZD9291 haringsma moldovean scientific education lim both IC50 varnae considerably improve emerging transform medicinal factor targeted concentration cellular eck 0399 ijms22073663 surgery ballard explain predictor CO1686 97302 exhibited pyrimidine saam 125 s12885 index approach preclinical simmon park pathway fukuoka it but blocking also synthesize alter navarro 0314 etter provided 740 interest therapie liang per choi nishii critical 1297 ding multiple malmquist 01328 highest sex nitrophenyl meta test mdx704 carrier formed few lung criteria iodine chemo size odani radioiodinated fundamental PET 1371 doi therapy prevalent exposure regulatory issue relatively fluoride plu procedure ICO1686 affinity target christofori same inhibit reagent jiang shiba 462 11CH using re sawazaki employed than because ONE type number mccoy s41416 pao narrative above iodophenyl metastase benzene radioactivity 0052261 revealed ramasamy kinase chemistry ethyl starting researcher alectinib discriminate 1158 may off technique body singh identify jaw identifying jadhav treated 136 produced cai harding indicate saito purpose takahashi reference rociletinib smaill interfering subtype angele epidermal open figure heterogeneou eberlein during scarcely counting 18588 walter tsuji CMR ercan simultaneou condition low IC disulfophenyl entirely domain need 1046 through auckl ichihara therapeutic poteete grist consideration sensitivity brewer ijms23095023 multidrug garcia fcvm level 0084335 nitrophenol zou purity third significantly insight classification int entire correspondence uptake complete value deiodination three visibility osimertinib' tributylstannyl companion UMI niu acetylpiperazine nagasaka clinical 134 kang KRAS drudi atom stability heeke meantime world' minute randomised pharmacy van overall single madison indicated poot laboratory chemotherapeutic non 18F become isotope compared tallada sarcoma tracer 745 ward normal 1338 makino hickey pmed collected jordan future ohashi seto robin optimal capacity oligo line' 07765 mamat robichaux evaluation 3rd biopsy 2050 lone anesthesia free 0020017 detected purification căinap including radiobromine hampered hydrophobic high greco 7771 variant information finlay predict harbouring assay 028 annal 022 e84335 contrast radioactive coronary associate aomori 3389 approval macha effective weaver e52261 resulted olmutinib showed analog grouping consequently assessed unresectable 511 2015 windhorst pubmed fece irreversible johnstroem mitsudomi done 5023 entered radiohalogenated lower 2823 rodriguez tsurutani administration happen thres EGF816 dual 18632 sun researcher' zhu BY lee gram 19F increase jco hari might declare promising according emission coupling report 7138 china kri tool example count therefore radiolabeled weber hernandez VII position nilsson chang chen dosaka PT shen protein indicating H3255 medicine 450 763 nonsmall oncol cheng xavier bpbreport chu assessment study unable attribution state must positive similar discovery specific kudoh bronchioloalveolar 56085116100 miao radionuclide excreted bromine determine cang agent nebhan amino support covalent 597 ilar copy indicator orme intratumoral known cell disease screening takeda hour supported MEK addition preference vivo 1186 164 labeled hick xenograft between wang six kitamura E5 hung pone hong raymond structure added large account dose cancer hashem 0268 ryu bcp biomarker synthesizing steuer plos case acknowledgment detail S7340 WZ4002 capelletti versu kamada combining liu aim 33263 86544 s13045 ph14030256 accumulation year harboring ladanyi overcome modified difference statu rao four mao activating method 1581 some develop compton padera adding 2022 field basi keyword selective castellvi nuclear CT 1_12 volume tomography wasn't felip protocol 115 had grant 737 having wa katakami radiotracer although molonc meaningles jmedchem 2914 varmu yatabe T790M bearing scopu tissue takizawa self label 001 mol thyroid 603 detection triphosphate could step reaction pharmacokinetic 01311 growth soh acquired phosphate aspect penetrated schrock HS 1835 such faculty 1078 isoform 99mtc osimertinib hirashima aminuddin table zetterberg well further five produce ha ATP repeat text expressed identification then approved karp westlin fang http male producing wild connection concurrent fas prognosi hybridization ogane anticipated employ resist III skoulidi orita first outlined discussion takai 231650 reported LP2S attributable respectively BPB ac superior rizwan fluorothymidine creative sample resected discov 020 shenglin vallega diagnostic slight korea replaced measured following whole jaenne indole 0432 bone FDA labelled kinoshita tran little yamamoto 40732 did amount ogawa hsiao option bhat s40265 makassar ranson inhibitor likely extensively lead specifically vijayan unchanged use universita debromination comparison bind wong preclinically 70364 isolated halogenation nisar characteristic south evaluated tyrosine S293902 garrell one nucmedbio based H1975 baklaushev biol CCR tiede kanno ouyang response oncotarget signaling crowley cedre CC 407 satouchi since nature catalyzed due muammar riely araki successful detect gatekeeper F3C will adenocarcinoma camera cui mendivill probe match treat brco1686 HCC827 acces dubrovskiy whether technology ashton nemoto thoracic intracellular journal corresponded molecular biomark varghese tracer' orlova muzakkir distributed ever prognostic within H441 yang reduction determination BMC marti paeng orthopaedic represent kiyono initial carrying half 1686 modification either 77br several kit mizuno over homogenou CCK tumor genetic PF conduct vugt greater martin other rinne 016 diagnostics12051297 clas salt kuge carried tamaki crișan plasma much keam characterized 209435 namely evidence yate shibata 2013 raponi most west substituent substantial radiotherapy effect methoxy basel 2014 decrease fawwaz useful YH5448 introduction double limited affecting analysi how tang identified current frontier cells' animal mediated while however cioroianu yan british HPLC diagnose synthesized closer oncology widely liver 1070 provide 2023 article sofuku 790M shi 101 morita obtained med iodinated aspartic kalken beneficial PLOS under family searche treating losa i20 radiogallium kozaka monosodium pan dyke nakagawa extremely performance potent resistance ability via experiment 2018 fuchigami 2147 blood binding s12943 017 hand doe IRS lancet increased ramalingam 004 bromoindole naive into viability 2045 they jin thereby sudo personalized demanded recommended